Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 9 |
List of Tables | 9 | 1 |
List of Figures | 10 | 1 |
Introduction | 11 | 1 |
Global Markets Direct Report Coverage | 11 | 1 |
Chronic Kidney Disease (Chronic Renal Failure) Overview | 12 | 1 |
Therapeutics Development | 13 | 2 |
Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) Overview | 13 | 1 |
Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) Comparative Analysis | 14 | 1 |
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Development by Companies | 15 | 3 |
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Investigation by Universities/Institutes | 18 | 1 |
Chronic Kidney Disease (Chronic Renal Failure) Pipeline Products Glance | 19 | 3 |
Late Stage Products | 19 | 1 |
Clinical Stage Products | 20 | 1 |
Early Stage Products | 21 | 1 |
Chronic Kidney Disease (Chronic Renal Failure) Products under Development by Companies | 22 | 3 |
Chronic Kidney Disease (Chronic Renal Failure) Products under Investigation by Universities/Institutes | 25 | 1 |
Chronic Kidney Disease (Chronic Renal Failure) Companies Involved in Therapeutics Development | 26 | 36 |
Acceleron Pharma, Inc. | 26 | 1 |
Angion Biomedica Corp. | 27 | 1 |
Astellas Pharma Inc. | 28 | 1 |
AstraZeneca Plc | 29 | 1 |
Bayer AG | 30 | 1 |
Bio-inRen | 31 | 1 |
BioAegis Therapeutics, Inc. | 32 | 1 |
Boehringer Ingelheim GmbH | 33 | 1 |
Bristol-Myers Squibb Company | 34 | 1 |
Cellmid Limited | 35 | 1 |
Complexa, Inc. | 36 | 1 |
CTI BioPharma Corp. | 37 | 1 |
Evotec AG | 38 | 1 |
F. Hoffmann-La Roche Ltd. | 39 | 1 |
Gilead Sciences, Inc. | 40 | 1 |
GNI Group Ltd. | 41 | 1 |
Intercept Pharmaceuticals, Inc. | 42 | 1 |
Lupin Limited | 43 | 1 |
Navya Biologicals Pvt Ltd | 44 | 1 |
Nippon Zoki Pharmaceutical Co., Ltd. | 45 | 1 |
Novartis AG | 46 | 1 |
Otsuka Holdings Co., Ltd. | 47 | 1 |
Prismic Pharmaceuticals, Inc. | 48 | 1 |
Prolong Pharmaceuticals, LLC | 49 | 1 |
ProMetic Life Sciences Inc. | 50 | 1 |
Reata Pharmaceuticals, Inc. | 51 | 1 |
Red Glead Discovery AB | 52 | 1 |
RegenMedTX, LLC | 53 | 1 |
Resverlogix Corp. | 54 | 1 |
Sphaera Pharma Pvt. Ltd. | 55 | 1 |
Stelic Institute &Co., Inc. | 56 | 1 |
Taisho Pharmaceutical Co., Ltd. | 57 | 1 |
Thrasos Therapeutics Inc. | 58 | 1 |
Toray Industries, Inc. | 59 | 1 |
VBS Pharmaceuticals | 60 | 1 |
Vicore Pharma AB | 61 | 1 |
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Assessment | 62 | 14 |
Assessment by Monotherapy Products | 62 | 1 |
Assessment by Combination Products | 63 | 1 |
Assessment by Target | 64 | 4 |
Assessment by Mechanism of Action | 68 | 4 |
Assessment by Route of Administration | 72 | 2 |
Assessment by Molecule Type | 74 | 2 |
Drug Profiles | 76 | 106 |
(palmidrol + silibinin) Drug Profile | 76 | 1 |
ambrisentan Drug Profile | 77 | 2 |
ANG-3070 Drug Profile | 79 | 1 |
ANG-3281 Drug Profile | 80 | 1 |
ANG-3586 Drug Profile | 81 | 1 |
apabetalone Drug Profile | 82 | 9 |
AS-2444697 Drug Profile | 91 | 1 |
bardoxolone methyl Drug Profile | 92 | 5 |
BI-655088 Drug Profile | 97 | 1 |
BLR-400 Drug Profile | 98 | 1 |
BMS-986177 Drug Profile | 99 | 1 |
BRN-1889 Drug Profile | 100 | 1 |
C-21 Drug Profile | 101 | 2 |
CAB-101 Drug Profile | 103 | 1 |
calcium succinate Drug Profile | 104 | 1 |
CAR Peptide Drug Profile | 105 | 1 |
cardiotoxin Drug Profile | 106 | 1 |
Cell Therapy for Chronic Kidney Disease and Metabolic Disorders Drug Profile | 107 | 1 |
CXA-10 Drug Profile | 108 | 2 |
dapagliflozin propanediol Drug Profile | 110 | 7 |
Drug for Kidney Diseases Drug Profile | 117 | 1 |
F-351 Drug Profile | 118 | 2 |
finerenone Drug Profile | 120 | 2 |
INT-767 Drug Profile | 122 | 1 |
KBP-5074 Drug Profile | 123 | 1 |
LHW-090 Drug Profile | 124 | 1 |
NAV-003 Drug Profile | 125 | 1 |
NZ-419 Drug Profile | 126 | 1 |
obinutuzumab Drug Profile | 127 | 7 |
pacritinib Drug Profile | 134 | 11 |
PBI-4050 Drug Profile | 145 | 5 |
PBI-4419 Drug Profile | 150 | 1 |
Recombinant Plasma Gelsolin Replacement for Renal Disease Drug Profile | 151 | 1 |
Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis Drug Profile | 152 | 2 |
Sanguinate Drug Profile | 154 | 2 |
Small Molecule to Agonize CaSR for Chronic Kidney Disease and Primary Hyperparathyroidism Drug Profile | 156 | 1 |
Small Molecule to Inhibit Sodium-Phosphate Cotransporter 2b for Chronic Kidney Disease and Hypertension Drug Profile | 157 | 1 |
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease Drug Profile | 158 | 1 |
Small Molecules for Chronic Kidney Disease Drug Profile | 159 | 1 |
Small Molecules for Chronic Kidney Disease Drug Profile | 160 | 1 |
Small Molecules to Inhibit SphK2 for Autoimmune Disorders, Chronic Kidney Disease, Fibrosis, Neurodegenerative Diseases and Oncology Drug Profile | 161 | 1 |
sotatercept Drug Profile | 162 | 5 |
SP-20103 Drug Profile | 167 | 1 |
SPR-494 Drug Profile | 168 | 1 |
STNM-310 Drug Profile | 169 | 1 |
Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease Drug Profile | 170 | 1 |
Synthetic Peptides for Chronic Kidney Disease Drug Profile | 171 | 1 |
TNT-009 Drug Profile | 172 | 2 |
tolvaptan Drug Profile | 174 | 4 |
torsemide ER Drug Profile | 178 | 1 |
TRC-101 Drug Profile | 179 | 1 |
TS-143 Drug Profile | 180 | 1 |
Vida-5 Drug Profile | 181 | 1 |
Chronic Kidney Disease (Chronic Renal Failure) Dormant Projects | 182 | 3 |
Chronic Kidney Disease (Chronic Renal Failure) Discontinued Products | 185 | 1 |
Chronic Kidney Disease (Chronic Renal Failure) Product Development Milestones | 186 | 10 |
Featured News &Press Releases | 186 | 1 |
Sep 12, 2016: AstraZeneca announces two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure | 186 | 1 |
Aug 05, 2016: CDSCO requests further data for granting additional indication for Ambrisentan tablet 5mg/10mg | 186 | 1 |
Aug 04, 2016: The Life Sciences Report Examines Resverlogix New Trial | 187 | 1 |
Jul 21, 2016: Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs | 187 | 1 |
May 24, 2016: Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis &Transplant Association Congress (ERA-EDTA) | 188 | 1 |
Nov 09, 2015: Resverlogix Presents Important New Data at the Annual American Society of Nephrology Kidney Week Conference | 189 | 1 |
Aug 04, 2015: International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone" | 189 | 2 |
Jun 02, 2015: Combination of Agents in NEFROSIL found to be Highly Effective in Renal Disease Model | 191 | 1 |
Jun 01, 2015: Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis &Transplant Association Congress | 191 | 1 |
Apr 07, 2015: Resverlogix Receives Two Patents For RVX-208 In China | 192 | 1 |
Nov 13, 2014: Sotatercept Data from the Phase 2a Clinical Trial in Hemodialysis Patients Presented at the American Society of Nephrology Kidney Week 2014 | 192 | 1 |
Oct 22, 2014: Acceleron Announces Educational Webcast on Chronic Kidney Disease - Mineral and Bone Disorder | 193 | 1 |
Jul 02, 2014: Future Development Direction for Bardoxolone Methyl (RTA 402) | 193 | 1 |
Apr 23, 2014: Acceleron and Celgene Announce Interim Clinical Data for Sotatercept Demonstrating Dose Dependent Increases in Hemoglobin in Patients with End Stage Renal Disease on Hemodialysis | 194 | 1 |
Mar 17, 2014: Acceleron and Celgene Announce Interim Clinical Data for Sotatercept in Patients with End Stage Renal Disease on Hemodialysis at the 2014 National Kidney Foundation Spring Clinical Meeting | 194 | 2 |
Appendix | 196 | 2 |
Methodology | 196 | 1 |
Coverage | 196 | 1 |
Secondary Research | 196 | 1 |
Primary Research | 196 | 1 |
Expert Panel Validation | 196 | 1 |
Contact Us | 196 | 1 |
Disclaimer | 197 | 1 |